More sales force cuts predicted for ’07

Share this article:
Expect to see continued field force downsizing in 2007 as pharmaceutical companies experiment with new sales execution strategies to improve their market position, said Mike Luby, CEO of prescribing behavior tracking firm TargetRx. 

“There are very few CEOs that are going to stand in front of Wall Street and say, ‘We think our sales force is too small,’” Luby told MM&M.

“What you’ll also see inside every company now is piloting,” he said. “They all are looking
for the new model and experimenting with new go-to-market strategies.”

Luby’s firm TargetRx recently completed its 2007 Sales and Marketing Quality Analysis designed to measure and actively manage sales force quality.

The analysis results reflect over 100,000 physician surveys completed during 2006 relating to physicians’ interactions with pharmaceutical company sales representatives.

Data were included for more than 100 brands in a diverse range of therapeutic areas.

According to the results, Boehringer Ingelheim, followed by Novartis and Schering-Plough, were ranked as the top three companies in overall sales and marketing quality by primary care physicians. Bristol-Myers Squibb, followed by Abbott and Novartis, were ranked the top three in overall sales and marketing quality by specialty physicians.

Luby said the analysis has been well received, especially at the executive levels of many of the companies included. 

“I think the industry has come to realize they need to do better at understanding the kind of
language that’s going to get physicians to prescribe for appropriate patients,” he said.

Other companies included in the analysis were Novo Nordisk, Eli Lilly, Johnson & Johnson, Sanofi-Aventis, Takeda, Merck, GlaxoSmithKline, Pfizer, Wyeth, AstraZeneca and Forest Pharmaceuticals.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...